The Acute Effects of Caloric Restriction on Anthropometrics, Metabolism, and Cardiovascular Health in Overweight Adults
Primary Purpose
Obesity, Overweight, Intermittent Fasting
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
3 day caloric restriction/metabolic reset
Sponsored by
About this trial
This is an interventional basic science trial for Obesity focused on measuring intermittent fasting, caloric restriction
Eligibility Criteria
Inclusion Criteria:
- Overweight or obese (body mass index, BMI > 27.5 kg/m2)
- Weight stable (± 4.4 lb) for > 6 months prior
- 25 to 65 years of age
- Participants will be expected to be otherwise relatively healthy without uncontrolled chronic disease (e.g. cardiovascular, metabolic, or pulmonary) and 2 or fewer positive risk factors for cardiovascular disease (CVD) (e.g. high blood pressure, high cholesterol, etc) as described by the American College of Sports Medicine (ACSM)/American Heart Association (AHA) Criteria.
- Cleared by Physician
Exclusion Criteria:
- Subjects who present with more than 2 CVD risk factors (AHA/ACSM criteria) or have uncontrolled/overt cardiovascular, pulmonary, or metabolic disease (Diabetes Mellitus)
- Not cleared by their physician.
- Recent blood donation (<8 weeks)
- Those who have cancer or are being treated for cancer.
- Women who are currently pregnant, breastfeeding, attempting to conceive, or amenorrheic (not associated with menopause).
- Anyone who presents with food allergies to coconuts, dairy, soy, stevia, or nuts will also be excluded.
- Those with eating disorders should not partake in this study.
Sites / Locations
- Skidmore College
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Pre- post-dietary intervention
Arm Description
Single arm pre-post dietary intervention (caloric restriction)
Outcomes
Primary Outcome Measures
Change in body weight
Change in total body weight
Secondary Outcome Measures
Change in total body water
Assessed via bioelectric impedance analysis (BIA)
Change in body fat (%)
Assessed via bioelectric impedance analysis (BIA)
Change in lean mass (kg)
Assessed via bioelectric impedance analysis (BIA)
Change in waist circumference
Changes in waist circumference (cm) using Gulick tape measure
Change in hip circumference
Changes in hip circumference (cm) using Gulick tape measure
Changes in waist to hip ratio
Changes in waist:hip ratio derived from waist and hip circumferences
Change in resting metabolic rate
Change in resting metabolic rate assessed using the ventilated hood technique and indirect calorimetry (TrueOne2400, Parvomedics).
Change in substrate utilization
Change in resting-fasted substrate utilization (Fat vs. Carbohydrate) using the ventilated hood technique and indirect calorimetry (TrueOne2400, Parvomedics).
Change peripheral blood pressure
Changes in peripheral blood pressure assessed using oscillometric cuff technique on the brachial artery (Sphygmocor Xcel).
Change in central blood pressure
Change in estimated central blood pressure, assessed using oscillometric cuff technique and generalized transfer function (Sphygmocor Xcel).
Change in augmentation index
Changes in augmentation index (a marker of vascular stiffness) will be assessed using oscillometric cuff technique and generalized transfer function (Sphygmocor Xcel).
Change in heart rate variability
Changes in time-domain based heart rate variability will be assessed using standard ECG with subsequent automated analysis with artifact correction (H7 PolarUSA and Elite HRV).
Changes in blood lipid profile
Changes in blood lipids (total Cholesterol, TC; low density lipoprotein LDL Cholesterol; high density lipoprotein, HDL Cholesterol; and TC:HDL ratio) will be assessed using standard techniques (Cholestech System)
Changes in blood glucose regulation
Changes in fasting blood glucose and insulin using standard techniques.
Changes in blood markers of inflammation
Changes in blood inflammatory markers (Tumor Necrosis Factor alpha (TNFa) and Cortisol) using standard techniques.
Changes in circulating regulators of metabolism
Changes in blood levels of the metabolically active hormones (thyroid stimulating hormone (TSH), protein yy (PYY), neuropeptide y (NPY), Ghrelin, and Leptin) using standard biochemical techniques.
Changes in perceptual indicators
Changes in self-reported sensations of hunger, fullness, satiety, and gastrointestinal discomfort will be assessed using visual analog scales (VAS). The VAS is 100 mm line ranging from 0 to 100, where a participant who marks 0 indicates "none" (not hungry at all or no gastrointestinal distress) vs. marking at 100 would indicate the maximal response ("severely hungry" or "severe gastrointestinal distress"). The hunger, fullness, and satiety ratings are not necessarily worse or better type outcomes, but simply descriptive. The magnitude is quantified by measuring the distance the participant marks on the 100mm line. In the case of gastrointestinal distress, scores over 51, or large increases in GID would be considered a less favorable outcome and the higher the score the worse the outcome on this specific item.
Changes in sleep health
Changes in sleep quantity and quality will be assessed using the consensus sleep diary, core form. This form records times for going to sleep, falling asleep, waking during the night, waking in the morning. There is only one likert type item which ask participants to subjectively rate the quality of sleep from very poor to very good, and reports of poor or very poor sleep would be considered worse outcomes, particularly those with changes in response to the dietary outcome.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05422391
Brief Title
The Acute Effects of Caloric Restriction on Anthropometrics, Metabolism, and Cardiovascular Health in Overweight Adults
Official Title
Evaluating the Short-Term Effects of 3 Days of Caloric Restriction/Intermittent Fasting Using the Plexus(R) Program on Anthropometrics, Metabolism, Markers of Cardiovascular Health in Overweight/Obese Men and Women
Study Type
Interventional
2. Study Status
Record Verification Date
December 2022
Overall Recruitment Status
Completed
Study Start Date
June 7, 2022 (Actual)
Primary Completion Date
September 7, 2022 (Actual)
Study Completion Date
November 17, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Skidmore College
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to document the efficacy of a 3 day intermittent fasting/caloric restriction (IF/CR) using the Plexus® 3 day reset program on body weight as well as regulatory parameters of metabolism and metabolic flexibility. This study will provide data on the acute efficacy regarding the program but also identify the potential underlying physiological mechanisms through which the dietary intervention may elicit improvements, and the participant experience of the program. Collectively, this will provide a window into the possible adaptations with a longer-term dietary intervention.
Detailed Description
According to the US Centers for Disease Control, more than 42% of adults are classified as obese, and approximately 74% of US adults are classified as overweight (body mass index of 25.0 to < 30 kg/m2) or obese (>30 kg/m2) (Ow/Ob). The costs on human health are profound, increasing the risk of heart disease, stroke, type 2 diabetes, and certain cancers, and ultimately increasing morbidity associated with these chronic diseases. Obesity and the negative sequelae inflict staggering economic costs, estimated at $147 billion, and that was in 2008. Therefore, understanding and developing interventions that can help address Ow/Ob can reduce the risk of chronic disease, reduce healthcare costs, and likely improve quality of life.
One such intervention has been through altering diet and/or physical activity. However, prior systematic review and meta-analysis suggests that when comparing diet alone vs. exercise alone, dietary interventions result in ~3-fold greater weight loss (11 vs 3 Δkg). While the additional benefits of exercise are not be discounted, engaging dietary approaches can be a highly effective way to promote weight loss. Caloric restriction (CR) has long been touted as an effective method of inducing weight loss, although there are also issues with adherence and maintenance with such an approach. This study is seeking to understand the acute metabolic changes with engaging in a 3-day caloric restriction, which would typically be part of an intermittent fasting dietary regimen.
Specific Aim 1. Document the efficacy of the 3 day IF/CR on inducing short term weight loss, the nature of the weight loss changes (body composition), changes in anthropometrics (waist and hip circumference), changes in resting metabolic rate and changes in metabolic flexibility (relative utilization of fats versus carbohydrates).
Specific Aim 2. Explore the physiological responses to the 3 day IF/CR with the Plexus 3 day reset program through analysis of blood plasma for levels of insulin, glucose, lipid profile (total cholesterol, high- and low-density cholesterol (HDL/LDL)), pro- and anti-inflammatory mediators (Tumor Necrosis Factor-alpha, TNFa and Cortisol, respectively), ketones, thyroid stimulating hormone (TSH), and hormones related to hunger and satiety and thus energy intake (protein YY (PYY), neuropeptide Y (NPY), Ghrelin, and Leptin).
Specific Aim 3. Ascertain any possible changes in clinically relevant parameters such as heart rate, heart rate variability (HRV), blood pressure (central and peripheral), and vascular stiffness (augmentation index, AIx).
Hypothesis: The investigators hypothesize that the nutritional intervention will induce weight loss, changes in anthropometrics/body composition (i.e. decreased body water), resting metabolic rate, and alterations in metabolic flexibility. These measures will be explained, at least, in part, by alterations in specific blood biomarkers. The investigators also hypothesize that the 3 day IF/CR will result in improved indicators of cardiovascular health.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Overweight, Intermittent Fasting
Keywords
intermittent fasting, caloric restriction
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
This study will utilize a pre-post interventional design to assess the acute effects of a 3 day caloric restriction protocol.
Masking
None (Open Label)
Allocation
N/A
Enrollment
15 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Pre- post-dietary intervention
Arm Type
Other
Arm Description
Single arm pre-post dietary intervention (caloric restriction)
Intervention Type
Dietary Supplement
Intervention Name(s)
3 day caloric restriction/metabolic reset
Intervention Description
Participants will consume ~500 kcal/day, using commercially available products (Plexus(r)), for 3 days, measuring physiological relevant parameters pre-and post-intervention.
Primary Outcome Measure Information:
Title
Change in body weight
Description
Change in total body weight
Time Frame
(days 0 and 4)
Secondary Outcome Measure Information:
Title
Change in total body water
Description
Assessed via bioelectric impedance analysis (BIA)
Time Frame
(days 0 and 4)
Title
Change in body fat (%)
Description
Assessed via bioelectric impedance analysis (BIA)
Time Frame
(days 0 and 4)
Title
Change in lean mass (kg)
Description
Assessed via bioelectric impedance analysis (BIA)
Time Frame
(days 0 and 4)
Title
Change in waist circumference
Description
Changes in waist circumference (cm) using Gulick tape measure
Time Frame
(days 0 and 4)
Title
Change in hip circumference
Description
Changes in hip circumference (cm) using Gulick tape measure
Time Frame
(days 0 and 4)
Title
Changes in waist to hip ratio
Description
Changes in waist:hip ratio derived from waist and hip circumferences
Time Frame
(days 0 and 4)
Title
Change in resting metabolic rate
Description
Change in resting metabolic rate assessed using the ventilated hood technique and indirect calorimetry (TrueOne2400, Parvomedics).
Time Frame
(days 0 and 4)
Title
Change in substrate utilization
Description
Change in resting-fasted substrate utilization (Fat vs. Carbohydrate) using the ventilated hood technique and indirect calorimetry (TrueOne2400, Parvomedics).
Time Frame
(days 0 and 4)
Title
Change peripheral blood pressure
Description
Changes in peripheral blood pressure assessed using oscillometric cuff technique on the brachial artery (Sphygmocor Xcel).
Time Frame
(days 0 and 4)
Title
Change in central blood pressure
Description
Change in estimated central blood pressure, assessed using oscillometric cuff technique and generalized transfer function (Sphygmocor Xcel).
Time Frame
(days 0 and 4)
Title
Change in augmentation index
Description
Changes in augmentation index (a marker of vascular stiffness) will be assessed using oscillometric cuff technique and generalized transfer function (Sphygmocor Xcel).
Time Frame
(days 0 and 4)
Title
Change in heart rate variability
Description
Changes in time-domain based heart rate variability will be assessed using standard ECG with subsequent automated analysis with artifact correction (H7 PolarUSA and Elite HRV).
Time Frame
(days 0 and 4)
Title
Changes in blood lipid profile
Description
Changes in blood lipids (total Cholesterol, TC; low density lipoprotein LDL Cholesterol; high density lipoprotein, HDL Cholesterol; and TC:HDL ratio) will be assessed using standard techniques (Cholestech System)
Time Frame
(days 0 and 4)
Title
Changes in blood glucose regulation
Description
Changes in fasting blood glucose and insulin using standard techniques.
Time Frame
(days 0 and 4)
Title
Changes in blood markers of inflammation
Description
Changes in blood inflammatory markers (Tumor Necrosis Factor alpha (TNFa) and Cortisol) using standard techniques.
Time Frame
(days 0 and 4)
Title
Changes in circulating regulators of metabolism
Description
Changes in blood levels of the metabolically active hormones (thyroid stimulating hormone (TSH), protein yy (PYY), neuropeptide y (NPY), Ghrelin, and Leptin) using standard biochemical techniques.
Time Frame
(days 0 and 4)
Title
Changes in perceptual indicators
Description
Changes in self-reported sensations of hunger, fullness, satiety, and gastrointestinal discomfort will be assessed using visual analog scales (VAS). The VAS is 100 mm line ranging from 0 to 100, where a participant who marks 0 indicates "none" (not hungry at all or no gastrointestinal distress) vs. marking at 100 would indicate the maximal response ("severely hungry" or "severe gastrointestinal distress"). The hunger, fullness, and satiety ratings are not necessarily worse or better type outcomes, but simply descriptive. The magnitude is quantified by measuring the distance the participant marks on the 100mm line. In the case of gastrointestinal distress, scores over 51, or large increases in GID would be considered a less favorable outcome and the higher the score the worse the outcome on this specific item.
Time Frame
Days 0 through 4
Title
Changes in sleep health
Description
Changes in sleep quantity and quality will be assessed using the consensus sleep diary, core form. This form records times for going to sleep, falling asleep, waking during the night, waking in the morning. There is only one likert type item which ask participants to subjectively rate the quality of sleep from very poor to very good, and reports of poor or very poor sleep would be considered worse outcomes, particularly those with changes in response to the dietary outcome.
Time Frame
Days 0 through 4
10. Eligibility
Sex
All
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Overweight or obese (body mass index, BMI > 27.5 kg/m2)
Weight stable (± 4.4 lb) for > 6 months prior
25 to 65 years of age
Participants will be expected to be otherwise relatively healthy without uncontrolled chronic disease (e.g. cardiovascular, metabolic, or pulmonary) and 2 or fewer positive risk factors for cardiovascular disease (CVD) (e.g. high blood pressure, high cholesterol, etc) as described by the American College of Sports Medicine (ACSM)/American Heart Association (AHA) Criteria.
Cleared by Physician
Exclusion Criteria:
Subjects who present with more than 2 CVD risk factors (AHA/ACSM criteria) or have uncontrolled/overt cardiovascular, pulmonary, or metabolic disease (Diabetes Mellitus)
Not cleared by their physician.
Recent blood donation (<8 weeks)
Those who have cancer or are being treated for cancer.
Women who are currently pregnant, breastfeeding, attempting to conceive, or amenorrheic (not associated with menopause).
Anyone who presents with food allergies to coconuts, dairy, soy, stevia, or nuts will also be excluded.
Those with eating disorders should not partake in this study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stephen Ives, Ph.D.
Organizational Affiliation
Skidmore College
Official's Role
Principal Investigator
Facility Information:
Facility Name
Skidmore College
City
Saratoga Springs
State/Province
New York
ZIP/Postal Code
12866
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
Requests for data may be reviewed on a case-by-case basis, after publication of initial findings.
Learn more about this trial
The Acute Effects of Caloric Restriction on Anthropometrics, Metabolism, and Cardiovascular Health in Overweight Adults
We'll reach out to this number within 24 hrs